



4
v2/3
12-19-01

Patent
Attorney's Docket No. 033052-004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Zhang et al.

Application No.: 09/892,327

Filed: June 26, 2001

For: Novel Compounds Possessing
Antibacterial, Antifungal or Antitumor
Activity

Group Art Unit: 1645

Examiner: Unassigned

RECEIVED
DEC - 5 2001
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650)622-2300

By: 
Gerald T. Swiss
Registration No. 30,113

Date:



Patent
Attorney's Docket No. 033052-004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)

Zhang et al.)

Application No.: 09/892,327)

Filed: June 26, 2001)

For: Novel Compounds Possessing)
Antibacterial, Antifungal or Antitumor)
Activity)

Group Art Unit: 1645

Examiner: Unassigned

RECEIVED
DEC - 5 2001
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed and listed below:

U.S. Patents:

1. U.S. Patent No. 4,912,199, Inventor(s): Lown et al., Issue date: March 27, 1990.
2. U.S. Patent No. 5,502,068, Inventor(s): Lown et al., Issue date: March 26, 1996.
3. U.S. Patent No. 5,616,606, Inventor(s): Lown et al., Issue date: April 1, 1997.

Articles/Reviews:

1. Bailly, Christian, et al., *Sequence-Specific DNA Minor Groove Binders. Design and Synthesis of Netropsin and Distamycin Analogues*, Bioconjugate Chemistry, Vol. 9, No. 5, (September/October 1998), pp. 513-538.


2. Chen, Yong-Huang, *Optimization of Cross-Linked Lexitropsins*, Journal of Biomolecular Structure & Dynamics, Vol. 14, No. 3, (November 3, 1996), pp. 341-355.
3. Filipowsky, Mark E., et al., *Linked Lexitropsins and the in Vitro Inhibition of HIV-1 Reverse Transcriptase RNA-Directed DNA Polymerization: A Novel Induced-Fit of 3.5 m-Pyridyl Bisdistamycin to Enzyme-Associated Template-Primer*, Biochemistry, (December 3, 1996), 35:40, pp. 15399-15410.
4. Fishleigh, Robert V. et al., *DNA Binding, Solubility, and Partitioning Characteristics of Extended Lexitropsins*, J. Med. Chem., 43, (2000), pp. 3257-3266.
5. Kissinger et al., Chem. Res. Toxicol., 3(2), (1990), pp. 162-168.
6. Lown, J. William et al., *Novel Linked Antiviral and Antitumor Agents Related to Netropsin and Distamycin: Synthesis and Biological Evaluation*, J. Med. Chem., 32:10, (1989), pp. 2368-2375.
7. Neamati, Nouri et al., *Highly Potent Synthetic Polyamides, Bisdistamycins, and Lexitropsins as Inhibitors of Human Immunodeficiently Virus Type 1 Integrase*, Molecular Pharmacology, 54, (1998), pp. 280-290.
8. Reddy, B.S. Praveen et al., *Synthetic DNA Minor Groove-Binding Drugs*, Pharmacology & Therapeutics, 84, (1999), pp. 1-111.
9. Sharma, Sanjay K., *Design and Synthesis of Novel Thiazole-Containing Cross-Linked Polyamides Related to the Antiviral Antibiotic Distamycin*, J. Org. Chem., 65, (2000), pp. 1102-1107.
10. Wang, Z., et al., Biochem. Pharmacol., 53, (1997), pp. 309-316.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Gerald F. Swiss
Registration No. 30,113

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650)622-2300

Date: